Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 Infection
Open Access
- 1 January 2001
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (1), 234-241
- https://doi.org/10.1128/jvi.75.1.234-241.2001
Abstract
Immune control of human immunodeficiency virus (HIV) is not restored by highly active antiretroviral therapies (HAART) during chronic infection. We examined the capacity of repeated structured therapeutic interruptions (STI) to restore HIV-specific CD4 and CD8 T-cell responses that controlled virus production. Eleven STI (median duration, 7 days; ranges, 4 to 24 days) were performed in three chronically HIV-infected patients with CD4 counts above 400/mm3and less than 200 HIV RNA copies/ml after 18 to 21 months of HAART; treatment resumed after 1 week or when virus became detectable. HIV-specific T-cell responses were analyzed by proliferation, gamma interferon (IFN-γ) production, and enzyme-linked immunospot assays. Seven virus rebounds were observed (median, 4,712 HIV-1 RNA copies/ml) with a median of 7 days during which CD4 and CD8 counts did not significantly change. After treatment resumed, the viral load returned below 200 copies/ml within 3 weeks. Significant CD4 T-cell proliferation and IFN-γ production against HIV p24 appeared simultaneously with or even before the virus rebounds in all patients. These CD4 responses lasted for less than 3 weeks and disappeared before therapeutic control of the virus had occurred. Increases in the numbers of HIV-specific CD8 T cells were delayed compared to changes in HIV-specific CD4 T-cell responses. No delay or increase in virus doubling time was observed after repeated STI. Iterative reexposure to HIV during short STI in chronically infected patients only transiently mobilized HIV-specific CD4 T1-helper cells, which might be rapidly altered by virus replication. Such kinetics might explain the failure at delaying subsequent virus rebounds and raises concerns about strategies based on STI to restore durable HIV-specific T-cell responses in chronic HIV infection.Keywords
This publication has 21 references indexed in Scilit:
- Strong Human Immunodeficiency Virus (HIV)–Specific CD4+T Cell Responses in a Cohort of Chronically Infected Patients Are Associated with Interruptions in Anti‐HIV ChemotherapyThe Journal of Infectious Diseases, 2000
- HIV-1–specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapyJCI Insight, 1999
- Functional T Cell Reconstitution and Human Immunodeficiency Virus–1–Specific Cell‐Mediated Immunity during Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 1999
- Control of HIV despite the Discontinuation of Antiretroviral TherapyNew England Journal of Medicine, 1999
- HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatmentAIDS, 1999
- Prolonged Suppression of Human Immunodeficiency Virus Type 1 (HIV?1) Viremia in Persons with Advanced Disease Results in Enhancement of CD4 T Cell Reactivity to Microbial Antigens but Not to HIV?1 AntigensThe Journal of Infectious Diseases, 1999
- Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 diseaseThe Lancet, 1998
- Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNAScience, 1998
- Resistance of HIV Type 1 to Proteinase Inhibitor Ro 31-8959AIDS Research and Human Retroviruses, 1995
- Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis.JCI Insight, 1992